Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

StatusRecruiting

PhasePhase 3

SponsorBristol-Myers Squibb

Started2025-09-22

View on ClinicalTrials.gov ↗

Amendment history

2026-09-23

Trial sites expanded: 402 → 408 locations

2026-08-20

Study Status, Contacts/Locations v26

Trial sites expanded: 394 → 402 locations

2026-07-22

Study Status, Contacts/Locations v25

Trial sites expanded: 391 → 394 locations

2026-07-03

Study Status, Contacts/Locations v24

Trial sites expanded: 383 → 391 locations

2026-06-15

Study Status, Contacts/Locations v23

Trial sites expanded: 363 → 383 locations

2026-05-26

Study Status, Contacts/Locations v22

Trial sites expanded: 357 → 363 locations

2026-05-06

Study Status, Contacts/Locations v21

Trial sites expanded: 351 → 357 locations

2026-04-17

Study Status, Contacts/Locations v20

Study sites350→351

2026-04-01

Study Status, Contacts/Locations v19

Trial sites expanded: 341 → 350 locations

2026-03-09

Study Status, Contacts/Locations v18

Study sites338→341

2026-02-26

Study Status, Contacts/Locations v17

Study sites332→338

2026-02-09

Study Status, Contacts/Locations v16

Study sites332 entries, revised

~~Local~~Omni ~~Institution~~Dermatology Omni -Dermatology Clinical ~~0496~~Trials Institute of Northwest Arkansas ~~Local~~Florida ~~Institution~~Academic -Dermatology ~~0501~~Center ~~Local~~Kuchnir ~~Institution~~Dermatology -& ~~0335~~Dermatologic Surgery ~~Local~~The ~~Institution~~Skin -Center ~~0105~~Dermatology Group ~~Local~~The ~~Institution~~Skin -Hospital Dr ~~0409~~Rodney Sinclair Pty Ltd. ~~Local~~Salford ~~Institution~~Care ~~- 0393 Local Institution - 0271 Local Institution - 0103 Local Institution - 0297~~Organisation

2026-02-02

Study Status, Contacts/Locations, IPDSharing v15

Study sites330→332

2026-01-23

Study Status, Contacts/Locations v14

Study sites327→330

2026-01-13

Study Status, Contacts/Locations v13

Study sites323→327

2025-12-22

Study Status, Contacts/Locations v12

Study sites317→323

2025-12-09

Study Status, Contacts/Locations v11

Study sites315→317

2025-12-01

Study Status, Contacts/Locations v10

Study sites303→315

2025-11-18

Study Status, Contacts/Locations v9

Study sites296→303

2025-11-04

Study Status, Contacts/Locations v8

Study sites292→296

2025-10-27

Study Status, Contacts/Locations v7

Study sites280→292

2025-10-16

Study Status, Contacts/Locations v6

Study sites274→280

2025-10-06

Study Status, Contacts/Locations v5

Start dateestimated 2025-10-30→confirmed 2025-09-22

Study sites274 entries, revised

~~Local~~Northridge ~~Institution~~Clinical Trials - ~~0411~~Elite Clinical Network ~~Local~~International ~~Institution~~GCC ~~- 0148~~Research

2025-09-19

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v4

Trial statusNot Yet Recruiting→Recruiting

Study sites265→274

2025-09-08

Study Status, Contacts/Locations v3

Study sites261→265

2025-08-29

Study Status, Contacts/Locations, References v2

Study sites241→261

2025-08-13

Study Status, Contacts/Locations v1

Study sites224→241

2025-08-04

Original filing

Bristol-Myers Squibb

311 trials monitored

See 15 trials at risk

Psoriasis

418 trials monitored

See 17 trials at risk

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

Trial Details

NCT Number	NCT07116967
Lead Sponsor	Bristol-Myers Squibb
Conditions	Plaque Psoriasis
Enrollment	3,040 participants
Start Date	2025-09-22
Primary Completion	2031-01-16 (estimated)
Study Completion	2031-01-16 (estimated)
Updated on ClinicalTrials.gov	2026-09-22